James Heller, chair of the firm's Products Liability Practice Group and vice chair of the Commercial Litigation Department, was quoted in Law360's article, "$28M Philly Xarelto Verdict Ripe For Reversal, Attys Say." After three prior bellwether trial losses, plaintiffs in litigation over the anticoagulant Xarelto are hoping to gain momentum following a $27.8 million verdict in Philadelphia on Tuesday, but attorneys say the award faces an uncertain future thanks to testimony that additional warnings would not have changed a doctor's decision to prescribe the drug. Jim told Law360 he doesn't believe the victory in Philadelphia will impact the bigger picture in Xarelto litigation given what he said were strong arguments against the verdict on post-trial motions and appeal. "If I were the defense, I would consider this a one-off," he said.

To read the full article, click here.